Jasjit Singh, MD
Psychiatry · Shreveport, LANPI 1265466197
Payments from drug & device makers
Across 1,082 payments — averaging $387.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$178K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$105K
- Axsome Therapeutics, Inc.$72K
- E.r. Squibb & Sons, L.L.C.$41K
- AbbVie$9K
- Sunovion Pharmaceuticals Inc.$6K
- plus $8K from 22 others
What the payments were for
- Consulting fees$41,03410%
- Speaking & faculty fees$326,69578%
- Travel & lodging$34,5278%
- Food & beverage$17,2314%
- Education$2540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 280 | $178,064 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 190 | $105,344 |
| Axsome Therapeutics, Inc. | 85 | $72,457 |
| E.r. Squibb & Sons, L.L.C. | 58 | $40,850 |
| AbbVie(2 entities) | 84 | $9,093 |
| Sunovion Pharmaceuticals Inc. | 68 | $5,564 |
| Teva Pharmaceuticals USA, Inc. | 43 | $3,628 |
| Lundbeck LLC | 53 | $740 |
| Otsuka America Pharmaceutical, Inc. | 45 | $650 |
| Neurocrine Biosciences, Inc. | 34 | $604 |
| Corium, LLC | 27 | $587 |
| Johnson & Johnson | 24 | $545 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $422 |
| Vanda Pharmaceuticals Inc. | 18 | $270 |
| Supernus Pharmaceuticals, Inc. | 6 | $145 |
| Shire North American Group Inc | 12 | $139 |
| Collegium Pharmaceutical, Inc. | 7 | $135 |
| AstraZeneca | 1 | $125 |
| Tris Pharma Inc | 5 | $81 |
| Ironshore Pharmaceuticals Inc. | 4 | $76 |
| Sage Therapeutics, LLC | 4 | $72 |
| Eisai Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Indivior Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$419,741 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $109,743 |
| Invega SustennaPaliperidone Palmitate | 27 | $91,903 |
| Austedo XrDeutetrabenazine | 15 | $54,667 |
| TrintellixVortioxetine Hydrobromide | 24 | $19,354 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,785 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,886 |
| Aripiprazole | 53 | $5,775 |
| LatudaLurasidone Hcl | 12 | $5,532 |
| Quetiapine Fumarate | 36 | $2,790 |
| Buspirone Hcl | 94 | $2,255 |
| Bupropion XlBupropion Hcl | 88 | $2,038 |
| Vilazodone Hcl | 12 | $1,684 |
| Duloxetine Hcl | 37 | $1,300 |
| Doxepin Hcl | 32 | $1,269 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 30 | $1,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $604 | $109,74313 claims |
| Johnson & JohnsonInvega Sustenna | $545 | $91,90327 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $3,628 | $54,66715 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $422 | $19,35424 claims |
| Alkermes, Inc.Lybalvi | $178,064 | $18,78512 claims |
| Axsome Therapeutics, Inc.Auvelity | $72,457 | $11,88611 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $5,564 | $5,53212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Shreveport
- Guy BrannonShreveport$1.4M
- Gregory BrownShreveport$495K
- James BookerShreveport$204K
- Shawn McNeilShreveport$105K
- Matthew MenardShreveport$101K
- Suresh SabbenahalliShreveport$10K
- Christopher BernadasShreveport$6K
- Daniel FeeneyShreveport$5K
- Kashinath YadalamLake Charles$3.8M
- Patrick HayesLake Charles$853K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.